Wednesday, May 25, 2011

Dynavax wraps up 2,400-patient hepatitis vaccine trial

Dynavax Technologies Corp. finished a Phase III test of its Heplisav hepatitis B vaccine candidate that enrolled 2,449 people.
Berkeley-based Dynavax (NASDAQ: DVAX) compared Heplisav to another vaccine, Engerix, in this year long test.
Results from the study should be ready in eight weeks.

No comments:

Post a Comment